Chao Joseph, Lee Jeeyun, Kim Kyung, Kang So Young, Lee Taehyang, Kim Kyoung-Mee, Kim Seung Tae, Klempner Samuel J, Lee Hyuk
Department of Medical Oncology and Therapeutics Research, City of Hope Comprehensive Cancer Center, Duarte, CA, United States.
Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.
Front Oncol. 2020 Feb 25;10:225. doi: 10.3389/fonc.2020.00225. eCollection 2020.
Intertumoral heterogeneity among actionable biomarkers including and has been observed to occur under therapeutic pressure in advanced gastric cancer. However, baseline intratumoral heterogeneity at diagnosis is understudied and may impact clinical outcomes. We sought to explore intratumoral heterogeneity in primary advanced gastric cancers via DNA sequencing from multi-region endoscopic sampling at diagnosis. Patients with newly diagnosed advanced gastric adenocarcinoma underwent endoscopic mapping and pre-determined 8-sector biopsy of the primary tumor with concurrent plasma cfDNA sampling. Biopsy samples were subjected to targeted next generation sequencing and plasma cfDNA was analyzed via a 28-gene cfDNA assay. Expectedly, we observed that the majority of genetic alterations were shared among multi-sector biopsies within the same gastric primary tumor. However, all samples contained private subclonal alterations between biopsy sectors, including actionable alterations in and . Cell free DNA analyses also exhibited both shared and non-shared alterations between mutations detected in cfDNA and tumor tissue biopsies confirming baseline intertumoral heterogeneity. This is the first dataset to confirm baseline intratumoral heterogeneity and confirms that multi-sector endoscopic biopsy is feasible and capable of capturing intratumoral heterogeneity among relevant genomic alterations in gastric cancer. Both multi-sector endoscopic biopsies and cfDNA analyses are complementary in capturing the diverse mutational landscape at disease presentation.
在晚期胃癌中,包括[具体生物标志物1]和[具体生物标志物2]在内的可操作生物标志物之间的肿瘤内异质性已被观察到在治疗压力下会出现。然而,诊断时的基线肿瘤内异质性研究不足,可能会影响临床结果。我们试图通过对诊断时多区域内镜取样进行DNA测序,来探索原发性晚期胃癌中的肿瘤内异质性。新诊断的晚期胃腺癌患者接受了内镜定位以及对原发性肿瘤进行预先确定的8个区域活检,并同时采集血浆游离DNA。活检样本进行靶向二代测序,血浆游离DNA通过28基因游离DNA检测进行分析。不出所料,我们观察到大多数基因改变在同一胃原发性肿瘤的多区域活检中是共享的。然而,所有样本在活检区域之间都包含独特的亚克隆改变,包括[具体基因1]和[具体基因2]中的可操作改变。游离DNA分析也显示了在游离DNA中检测到的突变与肿瘤组织活检之间既有共享改变也有非共享改变,证实了基线肿瘤间异质性。这是第一个证实基线肿瘤内异质性的数据集,并证实多区域内镜活检是可行的,并且能够捕捉胃癌相关基因组改变中的肿瘤内异质性。多区域内镜活检和游离DNA分析在捕捉疾病呈现时的多样突变格局方面是互补的。